% | $
Quotes you view appear here for quick access.

Facebook, Inc. (FB) Message Board

  • pressman_john pressman_john Jan 7, 2014 7:13 PM Flag

    Oppenheimer Gives CLDX $ 40 Target For Near Term Catalyst. read

    Oppenheimer Sees Five Biotech Stocks to Buy With Potential 50% Upside, or More
    By Lee Jackson January 7, 2014
    Celldex Therapeutics Inc. (NASDAQ: CLDX) focuses on developing therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines. Investors are interested in Celldex because of the unmet need therapies the company is developing. Celldex is working on drug indications that include therapies for glioblastoma, breast cancer, dense deposit disease and lymphoma. A recent secondary stock offering helped shore up the company coffers. The company is to update its CDX-1135 drug status, which could be a huge catalyst. The Oppenheimer price target is set at $40. The Thomson/First Call estimate is in line at $39. Celldex closed Monday at $22.33. A move to the target would be a 65% gain for shareholders

    SortNewest  |  Oldest  |  Most Replied Expand all replies
119.145+1.255(+1.06%)12:53 PMEDT